2M6 📈 Medtronic - Overview

Exchange: XETRA • Country: Ireland • Currency: EUR • Type: Common Stock • ISIN: IE00BTN1Y115

2M6: Implantable Pacemakers, Aortic Valves, Stents, Surgical Instruments, Insulin Pumps

Medtronic plc is a global leader in developing, manufacturing, and selling device-based medical therapies that cater to the diverse needs of healthcare systems, physicians, clinicians, and patients worldwide. With a rich history dating back to 1949, the company has established itself as a pioneer in the medical technology industry.

The company's Cardiovascular Portfolio segment offers a comprehensive range of products, including implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices. These devices are designed to treat various heart conditions, such as arrhythmias and heart failure. Additionally, the segment provides cardiac ablation products, insertable cardiac monitor systems, and TYRX products, which are used to treat conditions like atrial fibrillation and ventricular tachycardia. The segment also offers aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, which are used to treat conditions like aortic stenosis and pulmonary valve disease.

Medtronic's Neuroscience Portfolio segment focuses on developing medical devices and implants that cater to the needs of spinal surgeons, neurosurgeons, neurologists, pain management specialists, and other medical professionals. The segment offers spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, including the Accurian nerve ablation system. These products are designed to treat conditions like chronic pain, Parkinson's disease, and epilepsy. The segment also offers energy surgical instruments, which are used in various surgical procedures.

The Medical Surgical Portfolio segment provides a wide range of products, including surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, and AI-powered surgical video and analytics platforms. The segment also offers robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, and gastrointestinal and hepatologic diagnostics and therapies. Additionally, the segment provides patient monitoring and airway management products, which are used to ensure patient safety during surgical procedures.

Medtronic's Diabetes Operating Unit segment focuses on developing innovative products for people with diabetes. The segment offers insulin pumps and consumables, continuous glucose monitoring systems, and the InPen smart insulin pen system. These products are designed to help people with diabetes manage their condition more effectively and improve their quality of life.

Headquartered in Galway, Ireland, Medtronic plc is a publicly traded company listed on the XETRA stock exchange under the ticker symbol 2M6. The company's common stock is classified under the Health Care Equipment sub-industry, and its ISIN is IE00BTN1Y115. For more information, please visit the company's website at https://www.medtronic.com.

Additional Sources for 2M6 Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

2M6 Stock Overview

Market Cap in USD 110,425m
Sector Healthcare
Industry Medical Devices
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception

2M6 Stock Ratings

Growth 5y -10.4%
Fundamental 39.8%
Dividend 52.7%
Rel. Performance Sector 0.32
Analysts -
Fair Price Momentum 81.55 EUR
Fair Price DCF 115.45 EUR

2M6 Dividends

Dividend Yield 12m 3.41%
Yield on Cost 5y 3.19%
Annual Growth 5y -2.66%
Payout Consistency 91.23%

2M6 Growth Ratios

Growth Correlation 3m 50.4%
Growth Correlation 12m 49.3%
Growth Correlation 5y -41.7%
CAGR 5y -1.29%
CAGR/Mean DD 5y -0.07
Sharpe Ratio 12m 0.58
Alpha -9.79
Beta 0.65
Volatility 18.64%
Current Volume 0.5k
Average Volume 20d 1.7k
What is the price of 2M6 stocks?
As of December 04, 2024, the stock is trading at EUR 81.63 with a total of 518 shares traded.
Over the past week, the price has changed by +1.01%, over one month by -1.95%, over three months by +4.02% and over the past year by +16.17%.
Is Medtronic a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Medtronic (XETRA:2M6) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.77 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of 2M6 as of December 2024 is 81.55. This means that 2M6 is currently overvalued and has a potential downside of -0.1%.
Is 2M6 a buy, sell or hold?
Medtronic has no consensus analysts rating.
What are the forecast for 2M6 stock price target?
According to ValueRays Forecast Model, 2M6 Medtronic will be worth about 88.6 in December 2025. The stock is currently trading at 81.63. This means that the stock has a potential upside of +8.58%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 88.6 8.6%